Equities analysts expect Quintiles Transitional Holdings Inc. (NYSE:Q) to announce sales of $2.02 billion for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for Quintiles Transitional Holdings’ earnings, with estimates ranging from $2.00 billion to $2.03 billion. Quintiles Transitional Holdings posted sales of $1.14 billion in the same quarter last year, which would indicate a positive year over year growth rate of 77.2%. The business is expected to announce its next earnings results on Wednesday, November 1st.

According to Zacks, analysts expect that Quintiles Transitional Holdings will report full year sales of $2.02 billion for the current fiscal year, with estimates ranging from $8.00 billion to $8.09 billion. For the next fiscal year, analysts forecast that the firm will post sales of $8.52 billion per share, with estimates ranging from $8.44 billion to $8.61 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Quintiles Transitional Holdings.

Quintiles Transitional Holdings (NYSE:Q) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.04. The business had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.96 billion. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 14.23%. The firm’s revenue for the quarter was up 68.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 earnings per share.

Q has been the topic of a number of recent analyst reports. Citigroup Inc. reiterated a “neutral” rating and issued a $96.00 target price (up previously from $87.00) on shares of Quintiles Transitional Holdings in a research note on Wednesday, June 28th. Robert W. Baird upgraded Quintiles Transitional Holdings from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $76.00 to $93.00 in a research note on Friday, July 7th. Barclays PLC reiterated an “overweight” rating and issued a $98.00 target price (up previously from $90.00) on shares of Quintiles Transitional Holdings in a research note on Monday, July 17th. Zacks Investment Research upgraded Quintiles Transitional Holdings from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research note on Thursday, July 27th. Finally, William Blair upgraded Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and raised their price target for the company from $70.10 to $93.42 in a research note on Friday, August 4th. Eleven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Quintiles Transitional Holdings presently has a consensus rating of “Buy” and a consensus target price of $92.84.

ILLEGAL ACTIVITY WARNING: “Quintiles Transitional Holdings Inc. (Q) Expected to Announce Quarterly Sales of $2.02 Billion” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/quintiles-transitional-holdings-inc-q-expected-to-announce-quarterly-sales-of-2-02-billion/1610020.html.

Quintiles Transitional Holdings (NYSE:Q) traded up 0.03% during mid-day trading on Thursday, reaching $95.28. 103,685 shares of the company traded hands. The firm has a market capitalization of $20.63 billion, a P/E ratio of 276.17 and a beta of 0.62. Quintiles Transitional Holdings has a 12-month low of $70.10 and a 12-month high of $99.95. The company’s 50 day moving average price is $95.20 and its 200 day moving average price is $88.00.

In related news, insider Ari Bousbib sold 46,080 shares of Quintiles Transitional Holdings stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $94.91, for a total transaction of $4,373,452.80. Following the completion of the transaction, the insider now directly owns 1,036,839 shares in the company, valued at $98,406,389.49. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of Quintiles Transitional Holdings stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $94.52, for a total value of $945,200.00. Following the transaction, the insider now owns 27,340 shares of the company’s stock, valued at $2,584,176.80. The disclosure for this sale can be found here. Insiders have sold 14,198,382 shares of company stock valued at $1,361,834,375 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in shares of Quintiles Transitional Holdings by 4,217.1% in the first quarter. BlackRock Inc. now owns 7,098,723 shares of the medical research company’s stock valued at $571,660,000 after buying an additional 6,934,290 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Quintiles Transitional Holdings by 2.2% in the second quarter. Vanguard Group Inc. now owns 12,789,723 shares of the medical research company’s stock valued at $1,144,680,000 after buying an additional 280,893 shares in the last quarter. KBC Group NV increased its position in shares of Quintiles Transitional Holdings by 53.3% in the second quarter. KBC Group NV now owns 18,959 shares of the medical research company’s stock valued at $1,697,000 after buying an additional 6,591 shares in the last quarter. AXA increased its position in shares of Quintiles Transitional Holdings by 85.4% in the second quarter. AXA now owns 251,830 shares of the medical research company’s stock valued at $22,539,000 after buying an additional 115,993 shares in the last quarter. Finally, Key Square Capital Management LLC purchased a new stake in shares of Quintiles Transitional Holdings in the second quarter valued at approximately $2,738,000. Institutional investors own 93.21% of the company’s stock.

Quintiles Transitional Holdings Company Profile

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Get a free copy of the Zacks research report on Quintiles Transitional Holdings (Q)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.